Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
By Dean Seal
Shares of Cerus gained after positive results were disclosed in a Phase 3 trial of its INTERCEPT Red Blood Cells being transfused to complex cardiac surgery patients.
The stock rose 10% to $2.05 in the first few hours of the trading day. Shares are still 5% lower than where they started the year.
The biotechnology company said Tuesday that the trial met its primary efficacy endpoint and showed non-inferiority for the INTERCEPT blood cells compared with conventional red blood cells as measured by incidence of acute kidney injury.
Cerus anticipated initiating a premarket approval application with the U.S. Food and Drug Administration in the second half of next year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 19, 2024 12:12 ET (16:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits